HR 193119th CongressIn Committee

Maintaining Innovation and Safe Technologies Act

Introduced: Jan 3, 2025

Standard Summary

Comprehensive overview in 1-2 paragraphs

H.R. 193, the Maintaining Innovation and Safe Technologies Act, directs the Secretary of Health and Human Services to issue guidance by January 1, 2027 on how Medicare Part B should pay for remote monitoring devices that incorporate artificial intelligence (AI) and transmit patient data to a health care provider for management or treatment. The bill uses existing CMS communication channels to disseminate this guidance and focuses on AI-enabled devices such as continuous glucose monitors. It does not create new funding or change existing coverage rules itself, but it aims to clarify payment requirements to support adoption of AI-driven remote monitoring technologies under Medicare. In short, the bill seeks to reduce ambiguity around when and how AI-enabled remote monitoring devices will be reimbursed under Medicare Part B, potentially encouraging innovation while ensuring safety through clarified payment standards.

Key Points

1Short title: The Act may be cited as the “Maintaining Innovation and Safe Technologies Act.”
2Guidanced requirement: By January 1, 2027, the Secretary of Health and Human Services must issue guidance on Medicare Part B payment requirements for AI-enabled remote monitoring devices.
3Scope of devices: Applies to devices that have an AI component (for example, a continuous adjustment feature) and that transmit information to a health care provider for patient management and treatment.
4Mechanism for guidance: Guidance must be issued using existing communications channels within the Department of Health and Human Services.
5Legislative scope: The guidance concerns payment under Part B of the Medicare program (42 U.S.C. 1395j et seq.) and references the Social Security Act framework for Medicare.

Impact Areas

Primary group/area affected- Medicare beneficiaries who use AI-enabled remote monitoring devices (e.g., continuous glucose monitors) and their clinicians, as well as equipment suppliers and providers billing Medicare Part B.Secondary group/area affected- Medical device manufacturers and developers of AI-enabled health technologies seeking Medicare payment pathways.- Health care payers and providers who rely on Medicare reimbursement for remote monitoring devices.Additional impacts- Potential clarity and consistency in reimbursement practices for AI-driven remote monitoring, which could foster innovation and faster adoption of new technologies.- No new funding or explicit coverage expansion in the statute; the impact depends on the substance of the forthcoming guidance and how CMS applies Part B payment rules to these devices.- Possible downstream effects on costs, budgeting, and utilization within Medicare if guidance influences which AI-enabled devices are reimbursable and under what conditions.

Generated by gpt-5-nano on Nov 18, 2025